NCT04666740 trial: what clinicians have said so far
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
- NCT04666740 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
Discussed at: AACR Annual Meeting 2026, ESMO Gastrointestinal Cancers Congress 2026
We haven't built an HCP commentary report on NCT04666740 (pembrolizumab plus olaparib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04666740 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma; Homologous Recombination Deficiency (HRD)
- Interventions
- Pembrolizumab; Olaparib
- Arms
- Cohort A: Core HRD · Experimental
- Cohort B: Non core HRD · Experimental
- Cohort C: Platinum sensitive · Experimental
- Enrollment
- 63 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- Memorial Sloan Kettering Cancer Center with Merck Sharp & Dohme LLC
- Start
- Dec 18, 2020
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04666740 · updated Feb 18, 2026
Publications
linked from the registry- Park W, O'Connor CA, Chou JF, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Homsi R, Sivaprakasam K, Umeda S, Perry MA, Varghese AM, Yu KH, Balogun F, Zervoudakis A, Katz SS, Kim TH, Zhao K, Richards AL, Lecomte N, Martin Muldoon D, Karnoub E, Chatila W, Yang J, El-Dika I, Rao D, Joshi S, Foote MB, Sugarman R, Harding JJ, Epstein AS, Kelsen D, Chalassani S, Keane F, Schoenfeld JD, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas AI, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue MT, Santos E, Rolston V, Reyngold M, Wei AC, Tipping M, Basturk O, Berger M, Kihn Do R, Schattner M, Jarnagin WR, Riaz N, Balachandran V, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly EM. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med. 2026 May;32(5):1783-1793. doi: 10.1038/s41591-026-04299-5. Epub 2026 Mar 25. PubMed 41882405
- Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, Sivaprakasam K, Umeda S, Perry M, Varghese A, Yu K, Balogun F, Zervoudakis A, Katz S, Kim TH, Zhao K, Richards A, Lecomte N, Muldoon D, Karnoub E, Yang J, El-Dika I, Rao D, Smita J, Foote M, Sugarman R, Harding J, Epstein A, Kelsen D, Chalasani S, Keane F, Schoenfeld J, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas A, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue M, Balachandran V, Schattner M, Santos E, Rolston V, Reyngold M, Wei A, Homsi R, Tipping M, Basturk O, Berger M, Do R, Jarnagin W, Riaz N, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly E. Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial. Res Sq [Preprint]. 2025 Sep 1:rs.3.rs-7334701. doi: 10.21203/rs.3.rs-7334701/v1. PubMed 40951294